Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

(Yahoo! Finance) Jan 15, 2021 - Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy for patients with rectal cancer show that intratumoral injection of the product candidate was feasible and it was well tolerated at all dose levels.

FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba biotech

(Morningstar) Jan 15, 2021 - Steba biotech, pioneering developer of the IMmune Photo Activate Cancer Treatment (ImPACT), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for padeliporfin ImPACT for the treatment of adult patients with low-grade and unifocal high-grade Upper Tract Urothelial Cancer (UTUC).

AstraZeneca Lung Cancer Drug Gets Nod For New Dosing Regimen In EU, UK

(Reuters) Jan 15, 2021 - AstraZeneca Plc said on Friday its cancer drug Imfinzi had been approved in Europe and Britain for a spaced-out regimen in a common type of lung cancer to help reduce the frequency of hospital visits while continuing treatment. The British drugmaker said that an additional dosing option of a 1,500 mg fixed dose, given every four weeks, was approved for use in adults with advanced non-small cell lung cancer (NSCLC), whose tumours cannot be surgically removed.

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

(Morningstar) Jan 15, 2021 - NuCana plc today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.

Dana-Farber Launches Venture Fund Targeting Incurable Cancers

(BioPharma Dive) Jan 15, 2021 - Dana-Farber Cancer Institute is diving deeper into biotech financing, announcing Thursday the launch of Binney Street Capital, its first-ever venture fund.

Study Shows Sharp Decline In Cancer Screenings And Diagnoses During The First COVID-19 Surge

(Dana-Farber) Jan 14, 2021 - In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses, researchers at Dana-Farber/Brigham and Women’s Cancer Center document a substantial decline in cancer and precancer diagnoses at the Northeast’s largest health care system during the first peak of the pandemic because of a drop in the number of cancer screening tests performed. The findings, which confirm concerns that COVID-related restrictions may have delayed the detection and treatment of many cancers, were moderated somewhat by data showing that cancer screenings and diagnoses at the healthcare system largely rebounded to pre-pandemic levels in the months following the initial peak.

Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

(Morningstar) Jan 15, 2021 - Arcus Biosciences, Inc. today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at ASCO GI.

Enhertu Receives FDA Approval for Gastroesophageal, Gastric Cancer Subset

( Jan 15, 2021 - The Food and Drug Administration approved Enhertu to treat adults with locally advanced or metastatic HER2-positive gastroesophageal or gastric cancer who have previously received a trastuzumab-based treatment regimen. The decision was based on data from the multicenter DESTINY-Gastric01 trial.

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers

(Yahoo! Finance) Jan 15, 2021 - Five Prime Therapeutics today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer. Trial results were presented in a late-breaking oral presentation today by UCLA Health’s Zev Wainberg, M.D., at the 2021 ASCO GI. The FIGHT trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus placebo plus chemotherapy in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+), non HER2 positive frontline advanced gastric or GEJ cancer.

2021 GI Cancers Symposium: Bemarituzumab Improves Gastric Cancer Survival, Response Rates

(OBR) Jan 15, 2021 - Adding bemarituzumab to modified FOLFOX (mFOLFOX) chemotherapy significantly improves survival and response rates for patients with advanced gastric cancer. The approach was associated with an increase in corneal adverse events and stomatitis. Zev Wainberg, MD, presented these findings at the American Society of Clinical Oncology’s 2021 Gastrointestinal Cancers Symposium (Abstract 160).